Loading patent…
AssigneeThe General Hospital Corporation
InventorsKenneth D. Bloch, Fumito Ichinose, Warren M. Zapol
Estimating the term…
Methods for reducing, partially preventing or completely preventing nitric oxide (NO) inhalation-related impairment of HPV in a mammal are disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-reactive oxygen species (anti-ROS) agent, e.g., N-acetylcysteine, or a leukotriene blocker. Methods for reducing, partially preventing or completely preventing loss of pulmonary vasodilatory responsiveness to NO inhalation in a mammal are also disclosed. The methods include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-ROS agent a therapeutically effective amount of a leukotriene blocker.
A method for reducing, partially preventing or completely preventing nitric oxide inhalation-related impairment of hypoxic pulmonary vasoconstriction in a mammal, comprising:
The method of claim 1, further comprising co-administering an effective amount of a leukotriene blocker.
A method for reducing, partially preventing or completely preventing loss of pulmonary vasodilatory responsiveness to nitric oxide inhalation in a mammal, comprising:
The method of claim wherein the leukotriene blocker is montelukast, zafirlukast, or zileuton.
Dependencies are inferred from the claim text.